1.PSS IN THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA
Hongyi WANG ; Wei SUN ; Peirui SHI ;
Chinese Journal of Marine Drugs 1994;0(04):-
Using chemotherapy (DA or HA and ATRA) to treat 22 cases of acute promyelocytic leukemia following to give PSS (100mg/d X 7d) ,the patients complicated with DIC were treated then were given the chemotherapy,combined with PSS to end. The results showed that the complete remission rate of the therapy of APL with PSS was increased to
2. Postoperative complications and survival analysis of 1 118 cases of open splenectomy and azygoportal disconnection in the treatment of portal hypertension
Ruizhao QI ; Xin ZHAO ; Shengzhi WANG ; Kun ZHANG ; Zhengyao CHANG ; Xinglong HU ; Minliang WU ; Peirui ZHANG ; Lingxiang YU ; Chaohui XIAO ; Xianjie SHI ; Zhiwei LI
Chinese Journal of Surgery 2018;56(6):436-441
Objective:
To analyze the recent postoperative and long-term postoperative complications of open-splenectomy and disconnection in patients with portal hypertension.
Methods:
There were 1 118 cases with portal hypertension who underwent open splenectomy and azygoportal disconnection from April 2010 to September 2015 at Department of Surgery, People′s Liberation Army 302 Hospital. Retrospective case investigation and telephone follow-up were conducted in October 2016. All patients had history of upper gastrointestinal bleeding before operation. Short-term complications after surgery were recorded including secondary laparotomy of postoperative abdominal hemostasis, severe infection, intake disorders, liver insufficiency, postoperative portal vein thrombosis and perioperative mortality. Long-term data including postoperative upper gastrointestinal rebleeding, postoperative survival rate and incidence of postoperative malignancy were recorded, too. GraphPad Prism 5 software for data survival analysis and charting.
Results:
Postoperative short-term complications in 1 118 patients included secondary laparotomy of postoperative abdominal hemostasis(1.8%, 21/1 118), severe infection(2.9%, 32/1 118), intake disorders(1.0%, 11/1 118), liver dysfunction (1.6%, 18/1 118), postoperative portal vein thrombosis(47.1%, 526/1 118)and perioperative mortality(0.5%, 5/1 118). After phone call following-up, 942 patients′ long-term data were completed including 1, 3, 5 years postoperative upper gastrointestinal rebleeding rate(4.4%, 12.1%, 17.2%), 1, 3, 5-year postoperative survival rate(97.0%, 93.5%, 90.3%); the incidence of postoperative malignant tumors in 1, 3 and 5 years were 1.7%, 4.4% and 6.2%.
Conclusions
Reasonable choosing of surgical indications and timing, proper performing the surgery process, effective conducting perioperative management of portal hypertension are directly related to the patient′s short-term prognosis after portal hypertension. Surgical intervention can reduce the rates of patients with upper gastrointestinal rebleeding, improve survival, and do not increase the incidence of malignant tumors.